OGI ORGANIGRAM GLOBAL INC. IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1620737 · Reporting currency CAD · Fiscal year ends 09/30
Financial factors as of 2022-08-31 (FY2022), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | FY2024*2024-09-30 | FY2022*2022-08-31 | FY2021*2021-08-31 | FY2020*2020-08-31 | FY2019*2019-08-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 159.84M | 145.81M | 79.16M | 86.80M | 80.41M |
| Cost of revenue | 111.39M | 119.04M | 103.57M | 105.00M | 42.52M |
| Gross profit | 47.52M | 31.57M | -28.40M | -56.49M | 48.47M |
| R&D expense | 11.20M | 5.96M | 3.65M | 1.27M | 409,000 |
| SG&A expense | 45.87M | 42.91M | 29.92M | 28.00M | 18.59M |
| Operating income | -35.67M | -43.15M | -91.82M | -145.51M | 5.49M |
| Interest expense | — | 429,000 | 2.96M | 6.01M | 9.67M |
| Pretax income | -45.44M | -14.37M | -130.70M | -146.63M | -5.88M |
| Income tax | 0 | -88,000 | 0 | -10.47M | 3.63M |
| Net income | -45.44M | -14.28M | -130.70M | -136.16M | -9.54M |
| EBITDA | -31.82M | -37.85M | -89.35M | -144.00M | 6.15M |
| EPS (basic) | -0.48 | -0.18 | -0.51 | -0.79 | -0.07 |
| EPS (diluted) | -0.48 | -0.18 | -0.51 | -0.79 | -0.07 |
| Weighted avg. shares (diluted) | 95.29M | 77.23M | 256.12M | 178.06M | 151.54M |
| Balance sheet | |||||
| Cash & equivalents | 106.75M | 68.52M | 55.37M | 24.60M | 47.55M |
| Receivables | 37.15M | 46.37M | 21.04M | 14.75M | 16.54M |
| Inventory | 67.35M | 50.31M | 36.70M | 66.36M | 93.14M |
| Current assets | 262.22M | 221.62M | 260.62M | 170.20M | 196.28M |
| PP&E, netmay include right-of-use assets (IFRS) | 96.23M | 259.82M | 235.94M | 247.42M | 218.47M |
| Intangibles | — | 56.24M | 17.05M | 1.77M | 2.07M |
| Total assets | 407.86M | 577.11M | 554.02M | 435.13M | 428.52M |
| Current liabilities | 53.32M | 55.28M | 26.27M | 29.08M | 43.86M |
| Short-term debt | 60,000 | 80,000 | 80,000 | 11.60M | 3.51M |
| Long-term debt | 25,000 | 155,000 | 230,000 | 103.67M | 46.07M |
| Total debt | 85,000 | 235,000 | 310,000 | 115.27M | 49.58M |
| Total liabilities | 101.87M | 69.05M | 74.21M | 135.60M | 101.52M |
| Shareholders' equity | 305.99M | 508.06M | 479.81M | 299.53M | 327.01M |
| Net debt | -106.66M | -68.28M | -55.05M | 90.67M | 2.02M |
| Shares outstanding | 108.59M | 78.45M | 74.70M | 194.51M | 156.20M |
| Cash flow statement | |||||
| Operating cash flow | 3.87M | -36.21M | -28.59M | -45.12M | -35.08M |
| Capital expenditure | 4.73M | 48.75M | 11.76M | 77.22M | 108.76M |
| Free cash flow | -859,000 | -84.96M | -40.35M | -122.35M | -143.84M |
| Investing cash flow | -38.77M | 44.03M | -115.11M | -138.20M | -46.78M |
| Financing cash flow | 107.78M | 5.33M | 174.46M | 160.37M | 74.33M |
| Depreciation & amortization | 3.85M | 5.30M | 2.47M | 1.51M | 664,000 |
| Stock-based compensation | 7.18M | 5.13M | 3.90M | 7.80M | 14.89M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.